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Abstract
The extensive world-wide morbidity and mortality caused by influenza A viruses highlights the need for new insights into the
host immune response and novel treatment approaches. Cationic Host Defense Peptides (CHDP, also known as antimicrobial
peptides), which include cathelicidins and defensins, are key components of the innate immune system that are upregulated
during infection and inflammation. Cathelicidins have immunomodulatory and anti-viral effects, but their impact on influenza
virus infection has not been previously assessed. We therefore evaluated the effect of cathelicidin peptides on disease caused
by influenza A virus in mice. The human cathelicidin, LL-37, and the murine cathelicidin, mCRAMP, demonstrated significant
anti-viral activity in vivo, reducing disease severity and viral replication in infected mice to a similar extent as the well-
characterized influenza virus-specific antiviral drug zanamivir. In vitro and in vivo experiments suggested that the peptides may
act directly on the influenza virion rather than via receptor-based mechanisms. Influenza virus-infectedmice treatedwith LL-37
had lower concentrations of pro-inflammatory cytokines in the lung than did infected animals that had not been treated with
cathelicidin peptides. These data suggest that treatment of influenza-infected individuals with cathelicidin-derived
therapeutics, or modulation of endogenous cathelicidin production may provide significant protection against disease.
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Introduction
Infection with influenza viruses is a significant cause of
morbidity and mortality. Vaccination can help protect against
prevalent subtypes of influenza, but new subtypes represent a
global pandemic threat, and emerging resistance to neuraminidase
(NA) inhibitors (the current first-line therapy) is of serious concern.
Thus, in addition to effective vaccination strategies, the develop-
ment of novel, alternative therapeutics is of great importance.
Innate immune mechanisms are critical to the host response to
respiratory infection with influenza virus [1]. As well as cytokines
and chemokines, both cellular responses (such as neutrophils,
macrophages, and NK cells) and other soluble factors found within
airway surface liquid (such as defensins and collectins) have been
shown to assist in the containment and clearance of an initial
influenza infection [2,3]. The effectiveness of these innate
responses to virus at the primary site of infection is likely to be
critical to the pathological outcomes of the disease, and targeting
these responses may lead to novel therapeutic agents.
Important components of early innate immunity are cationic
host-defense peptides (CHDP; also known as antimicrobial
peptides). Although initially described primarily as antibacte-
rial agents, we and others have characterised them as
modulators of inflammation and immunity [4,5], and recent
studies have also demonstrated direct antiviral potential
[6,7,8,9,10]. The two major families of CHDP in mammals
are cathelicidins and defensins. Whereas the multitude of
defensins and the very mild phenotypes observed in specific
defensin-null mice [11,12] suggests considerable functional
redundancy, humans and mice express a single cathelicidin.
Increased susceptibility to infection is observed in individuals
with morbus Kostmann (in which neutrophils are cathelicidin-
deficient) [13], and mice deficient in the murine cathelicidin
mCRAMP/Camp have significantly increased susceptibility to
bacterial infection in multiple systems, including the lung
[14,15,16,17,18]. Although the precise mechanisms involved,
and the relative roles of microbicidal activity and immuno-
modulatory functions remain unknown, these studies clearly
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demonstrate the importance of this CHDP in host defence
against bacterial infection.
The sole human cathelicidin hCAP-18 (CAMP) is stored in
neutrophil-specific granules and is inducible in epithelial cells and
macrophages [19]. LL-37 is the predominant active CHDP,
generated from hCAP-18 by proteinase-3 [20]. LL-37 can be
detected in airway surface liquid, plasma, sweat and other body
fluids, and is upregulated in response to infection and inflamma-
tion. Although the primary source of LL-37 is pre-stored hCAP-18
in neutrophil granules, inducible production in epithelial cells may
be important in the earliest innate response to pathogens.
Interestingly, the upregulation of LL-37 expression in epithelial
cells and macrophages has been shown to be vitamin-D dependent
[21,22,23], including in response to respiratory syncytial virus
[21]. Vitamin D-dependent upregulation of LL-37 may therefore
help explain the protective effect of vitamin D against viral
infection [24,25], raising the possibility of an anti-viral role for LL-
37 in the lung.
Evidence for cathelicidin-mediated anti-viral functions have
been provided by recent demonstrations of inhibition of HIV-1
replication [10], reduced vaccinia plaque formation in vitro, and
increased susceptibility of cathelicidin-deficient mice to eczema
vaccinatum following vaccinia virus inoculation [26]. Based on the
antiviral activity of LL-37 and its importance in the response to
lung infections, as well as the need for new antiviral drugs against
influenza, this study assessed the potential for cathelicidins to exert
antiviral effects against influenza virus in in vitro and in vivo models
of infection.
Results
LL-37 Protects Mice Against Influenza Virus Disease
To determine if LL-37 displayed antiviral activity in a murine
model of lethal influenza virus infection, mice (6–8 week old,
female Balb/C) were treated with nebulized LL-37 for 1 day prior
to and for 7 days post infection with 10650% Mouse Lethal Doses
(MLD50) A/Puerto Rico/8/1934 (H1N1) virus (PR/8). Nebulized
zanamivir and a scrambled LL-37 peptide were used as positive
and negative controls respectively. Mouse body weight and
survival were monitored for 14 days following infection. Mice
infected with PR/8 and treated with nebulized saline or control
scrambled peptide all showed severe disease with severe weight
loss by day 8 post infection. In contrast, mice that received
treatment with either LL-37 or the antiviral drug, zanamivir,
showed significantly decreased body weight loss (P#0.05 and
P#0.01 respectively) at 7 dpi (maximum weight loss observed was
,20%). Weight loss in LL-37 and zanamivir treated mice ceased
around day 9 (Figure 1A).
Mice infected with PR/8 and nebulized with either saline or
scrambled peptide either died or were required to be euthanized
due to severe disease 8–9 days after infection, whereas mice that
had received either nebulized LL-37 or nebulized zanamivir
showed a significant increase in survival (P#0.001; Figure 1B).
Survival of mice receiving LL-37 was comparable to that of mice
receiving zanamivir (approximately 60% of mice survived in both
treatments) clearly demonstrating that therapeutic use of LL-37
was able to reduce the severity of the influenza virus infection to a
similar extent as the well characterized antiviral drug zanamivir, a
current first-line human therapeutic.
In order to assess whether changes in disease severity could be
attributed to a reduced viral load in the lungs, groups of mice were
euthanized at 3 days post infection and lung virus titers were
measured by plaque assay. Compared to control-treated mice,
mice that had been treated with LL-37 showed significant
reduction of approximately 70-80% in lung virus titer at 3 days
post infection (p#0.05), a similar level of reduction as seen after
zanamivir treatment (Figure 1C). Treatment with control
scrambled peptide had no effect on lung virus titers demonstrating
that the protective response was not a non-specific effect of
treatment with a charged peptide. These data demonstrate the
antiviral potential of the therapeutic use of LL-37.
Cathelicidins Show Species-Specific Antiviral Effects
LL-37 is a human cathelicidin, although it has previously been
shown to have antimicrobial effects in mouse models of infection
[27]. To determine if other peptides of the cathelicidin family
also conferred protection against influenza virus in vivo, mice were
treated with the murine mCRAMP peptide or the porcine
Protegrin-1 peptide for 1 day prior to and for 7 days post infection
with 10 MLD50 A/PR/8/34 (H1N1) virus. Nebulized zanamivir
was used as a positive control. As with LL-37, mice infected with
PR/8 and nebulized with mCRAMP lost less weight when
compared to control mice that had received only nebulized saline
(Figure 2A). Treatment with mCRAMP also dramatically resulted
in significantly enhanced survival (Figure 2B, p,0.001) and
reduced lung virus titers by approximately 70–80% (Figure 2C).
Animals treated with mCRAMP showed similar weight loss,
survival, and lung virus titers as those treated with zanamivir
(Figure 2A–C). In contrast, mice that had received treatments with
nebulized Protegrin-1 peptide lost weight to the same extent as the
control-treated animals (Figure 2D), and did not show any
statistically significant increase in survival (Figure 2E), or reduction
in lung virus titers (Figure 2F).
These data further demonstrate the specificity of the anti-viral
effect between cathelicidins from divergent species. They also
indicate that murine and human cathelicidins may play a
significant role in innate host defense against influenza infection
and demonstrate the capacity to enhance this defense with
increased levels of native cathelicidins.
Cathelicidins Mediate Changes in Lung Cytokine
Concentrations Following Influenza Virus Infection
Cathelicidins have been shown to elicit a number of protective
mechanisms in host defense against infection. To determine
whether LL-37 might be protecting against influenza infection by
modulating the inflammatory response in the lung, a number of
cytokines in the bronchoalveolar lavage (BAL) fluid of mice were
assessed using a BioPlex assay. Groups of 5 mice were treated with
nebulized LL-37 or with saline for 1 day prior to and 2 days after
infection with A/PR/8/34 (H1N1). Other groups were not
infected and received either LL-37 only or saline only. After
PR/8 infection, a number of inflammatory cytokines were found
to be increased in the BAL fluid of control infected mice.
Significant (p#0.05) increases of IL-1b, GM-CSF, KC and
RANTES were observed in the BAL fluid three days after
infection. Treatment with LL-37 did not significantly alter
cytokine concentrations in the absence of influenza virus infection.
However, in infected mice treated with LL-37 the BAL fluid
concentrations of IL-1b, GM-CSF, KC and RANTES were found
to be unchanged compared with uninfected controls, and IL-1b
and GM-CSF were significantly lower (p#0.05) than in PR/8
infected control animals. Mice infected with PR/8 also showed a
non-significant increase in the BAL fluid concentration of MIP-1a
compared to naı¨ve untreated animals (Figure 3E) and this increase
was ameliorated when mice were nebulized with LL-37.
These data demonstrate the capacity of LL-37 treatment to
modulate the inflammatory response to influenza virus. They
demonstrate that LL-37 treatment does not protect against
LL-37 and Influenza
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influenza infection by promoting sustained inflammation, but
suggest the possibility that cathelicidins may be protective by
inhibiting excessive inflammation, or may have a direct anti-viral
effect on influenza virus.
Cathelicidins show antiviral activity against influenza
virus in vitro
To assess the direct antiviral activity of cathelicidins in vitro, we
incubated PR/8 with varying concentrations of cathelicidin
peptides or control scrambled peptide, for 1 hour at room
temperature and measured virus titer by plaque assay. Exposure
to physiologically relevant concentrations of LL-37 led to
approximately 90% reductions in virus titer (p#0.05) (Figure 4A).
Control scrambled LL-37 had no effect on the virus titer. The
murine mCRAMP peptide also displayed anti-influenza virus
activity and induced a significant decrease in virus titer following
exposure (P#0.05; Figure 4B). However, consistent with the in vivo
observations, the porcine cathelicidin Protegrin-1 did not
demonstrate any anti-influenza activity in this assay (Figure 4B).
We also tested the effect of cathelicidins on a different subtype of
influenza virus, A/Udorn/307/72 (H3N2). As with PR/8,
exposure to physiologically relevant concentrations of LL-37 and
mCRAMP caused a significant reduction in virus titer (P#0.01;
Figure 4C).
These data support the hypothesis that the antiviral effects of
these cathelicidins are at least partially due to direct effects of the
peptides upon the influenza virion.
D-Isomer cathelicidins inhibit influenza virus
To further test whether the anti-influenza activity observed with
LL-37 and mCRAMP peptides was related to the physical
properties of the peptide or whether interactions with a specific
Figure 1. LL-37 Protects Mice Against Influenza Virus Disease. (A,B) Groups of 5 mice were inoculated with 10 MLD50 of A/Puerto Rico/8/1934
influenza virus by the intranasal route on day 0. Mice were nebulized with 200 ml of saline (control), zanamivir (500 mg/ml), LL-37 peptide (500 mg/ml)
or scrambled LL-37 control peptide (500 mg/ml) once daily from day -1 to day 7. Mouse body weight (A) and survival (B) was monitored daily up to 14
days post infection. Data represent mean values 6 SEM, for three independent experiments. Statistical analysis was performed using Kaplan Meier
with a Mantel-Cox (log rank) test. Survival curves obtained with Zanamivir and LL-37 treatments were significantly different (P#0.001) compared to
saline control treatment. There was no difference between saline treated and sLL-37 treated groups. (C) Groups of three mice (Female, 6–8 week old
Balb/c) were inoculated with 10 MLD50 of A/PR/8/34 virus intranasally on day 0. Mice were nebulized with 200 ml of saline (control) zanamivir (500 mg/
ml), LL-37 peptide (500 mg/ml) or scrambled LL-37 control peptide (500 mg/ml) once daily from day -1 to day 2. Mice were euthanized on day 3 and
viral titer in the lungs was assessed by plaque assay. Figure is representative of three independent experiments. Figure shows mean values 6 SEM.
Statistical analysis was performed using a Student t-test to compare virus infected animals with virus/peptide and virus/zanamivir treated animals
(*P#0.05).
doi:10.1371/journal.pone.0025333.g001
LL-37 and Influenza
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receptor might be involved, we synthesized LL-37 and mCRAMP
peptides using only D-amino acids instead of L-amino acids and
tested the antiviral properties of the peptides both in vitro and in
vivo. Notably, both LL-37 and mCRAMP that had been
synthesized with D-amino acids demonstrated effective antiviral
activity in vitro, reducing titers as effectively as the L-peptides
(Figure 5D). Consistent with this in vitro effect, the D-peptides
were also effective in vivo. Mice were treated with nebulized D-
LL-37 and D-mCRAMP for 1 day prior to and for 7 days post
infection with 10MLD50 A/PR/8/34 (H1N1) virus. Mice were
monitored for 14 days following infection. Mice that had received
treatment with either of the D-analogs showed less body weight
loss compared to control infected animals (Figure 5A) and
survival was dramatically enhanced (Figure 5B). All control
infected mice succumbed to PR/8 infection by day 8. However,
there was significantly greater survival in the mice treated with D-
LL-37 (80%) or D-mCRAMP (100%) (Figures 5A and 5B,
P#0.001). Additionally, lung virus titers assessed at 3dpi were
markedly lower in mice treated with D-peptides compared with
mice that had been treated with nebulized saline only (P#0.05;
Figure 5C). Weight loss, survival and lung titers in D-peptide
treated mice were comparable to those in mice treated with
zanamivir. These data suggest that the antiviral effects mediated
by cathelicidins in vivo may be due to physical properties of the
peptides rather than interactions with stereoisomer-specific
receptors.
Discussion
Many studies have demonstrated that cationic host defense
peptides (CHDP, also known as antimicrobial peptides) can
display potent activity against bacteria and viruses. In addition to
the broad spectrum antibacterial potential, the cathelicidin family
of peptides has previously been shown to display antiviral activity
towards human immunodeficiency virus (HIV-1), vaccinia virus,
adenovirus and herpes simplex virus-1 and -2 [6,10,26,28]. In
addition, the other major human family of CHDP, defensins, have
also been reported to show anti-influenza virus properties [2,3,29].
In this study we demonstrate that human and murine
cathelicidin peptides display antiviral activity against influenza
virus in vitro and in vivo and that therapeutic administration of these
peptides can provide significant protection against influenza virus
infection in a mouse model. In addition to enhancing our
understanding of the role of cathelicidins in innate host defense
against influenza virus, these findings may point towards future
therapeutic approaches for influenza virus infection.
Our data demonstrate that delivery of nebulized LL-37 peptide
to mice infected with a lethal A/Puerto Rico/8/1934 (H1N1)
Figure 2. Cathelicidins Show Species-Specific Antiviral Effects. (A,B,D,E) Groups of 5 mice were infected with 10 MLD50 of A/PR/8/34
influenza virus via intranasal administration on day 0. Mice were nebulized with 200 ml of saline (control), zanamivir (500 mg/ml), the murine
cathelicidin mCRAMP (500 mg/ml) (A and B) or the porcine cathelicidin Protegrin-1 (500 mg/ml) (D and E) once daily from day -1 to day 7. Mouse body
weight (A, D) and survival (B, E) was monitored daily up to 14 days post infection. Data represent mean values 6 SEM, for three independent
experiments (A and B) or one experiment (D and E). Statistical analysis was performed using Kaplan Meier with a Mantel-Cox (log rank) test. Survival
curves obtained with Zanamivir and mCRAMP treatments were significantly different (P#0.001) compared to saline control treatment. There was no
difference between saline treated and Protegrin treated groups. (C, F) Groups of three mice were infected with 10 MLD50 of A/PR/8/34 virus via
intranasal administration on day 0. Mice were nebulized with 200 ml of saline (control), zanamivir (500 mg/ml), the murine cathelicidin mCRAMP
(500 mg/ml) or the porcine cathelicidin Protegrin-1 (500 mg/ml) once daily from day -1 to day 2. Mice were euthanized on day 3 and viral titer in the
lungs was assessed by plaque assay. Figure shows mean values 6 SEM. Statistical analysis was performed using an unpaired t-test to compare virus
infected animals with virus/peptide and virus/zanamivir treated animals (*P#0.05, **P#0.01, ***P#0.001).
doi:10.1371/journal.pone.0025333.g002
LL-37 and Influenza
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influenza virus infection increased survival and decreased body
weight loss when compared to either a scrambled control LL-37
peptide or saline control. Mice treated with the LL-37 peptide also
displayed significantly reduced lung virus titers. Similarly, the
mouse cathelicidin peptide, mCRAMP significantly reduced lung
titers of PR8 and increased survival with reduced clinical disease
(as measured by weight loss). The protective effects of LL-37 and
mCRAMP were similar in magnitude to that of the well-
characterized antiviral drug zanamivir.
The porcine neutrophil-derived cathelicidin peptide, Protegrin-
1, did not appear to have any effect in the mouse model of
infection. Previous studies in mice have demonstrated that
Protegrin-1 shows potent antiviral activity towards HSV-1, HIV-
1 and Lentivirus together with antibacterial activity towards
Haemophilus, Chlamydia and Actinobacillus among others [30,31,32].
However, this activity did not extend to extend to influenza virus
in either in vitro or in vivo experiments, indicating that that anti-
influenza virus activity of cathelicidins is not inherent in all
cathelicidin peptides. Further experiments will be needed to
determine the reasons for this difference, and whether Protegrin-1
may be protective against swine-origin 2009 pandemic H1N1
human influenza viruses rather than the human-origin, mouse-
adapted PR/8 virus.
LL-37 has been shown to have both direct microbicidal
potential and a broad range of immunomodulatory properties;
including direct [33,34,35] and indirect chemotactic functions
[36,37], and the capacity to modulate neutrophil function [38], the
death of neutrophils [39,40,41] and infected epithelial cells [42],
autophagy in infected macrophages [43], and the differentiation
and function of dendritic cells [44,45]. Many of these properties
have the potential to influence the outcome of influenza infection
in vivo, and dissecting the key mechanisms involved remains a
future challenge. In particular, cathelicidins are capable of
inducing chemokine and cytokine responses [36,37,46], and of
modulating cytokine responses to pathogen-associated stimuli;
including the inhibition of pro-inflammatory responses to
lipopolysaccharide [36,47,48] and enhanced responses to IL-1b
[49]. Infection with influenza virus induces expression of multiple
pro-inflammatory cytokines, an effect that is essential for host
defense against influenza virus infection [1]. In particular IL-1b
has been shown to be a critical component of host defense against
influenza in murine lung infection [50,51,52], induced in response
to viral activation of the NLRP3 inflammasome, with influenza
stimulating increased IL-1b production by macrophages [53].
Furthermore, influenza virus has been shown to employ multiple
strategies to subvert the immune response [54], including
suppression of IL-1b activity [55]. To test whether LL-37
modulated the inflammatory cytokine response to influenza, we
measured cytokines in the bronchoalveolar lavage (BAL) fluid of
mice following infection in the presence or absence of LL-37
Figure 3. Cathelicidins Mediate Changes in Lung Cytokine Concentrations Following Influenza Virus Infection. Groups of 5 mice were
infected with 10 MLD50 of A/PR/8/34 influenza virus via intranasal administration on day 0. Mice were nebulized with 200 ml of saline (control), or LL-
37 peptide (500 mg/ml) once daily from day -1 to day 2. Mice were euthanized on day 3 and concentration of the indicated cytokines in the
bronchoalveolar lavage (BAL) fluid were measured by BioPlex assay. Figures show mean values 6 SEM. Statistical analysis was performed using an
two-way analysis of variance (ANOVA) (*P#0.05).
doi:10.1371/journal.pone.0025333.g003
LL-37 and Influenza
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treatment. As expected, PR/8 infection led to marked upregula-
tion of multiple inflammatory cytokines three days after infection.
However, this increase was not observed in LL-37-treated mice
suggesting either that the inflammatory response was diminished
by LL-37, or that virus replication was inhibited to the point that
an inflammatory response was not induced or was resolved by day
three after infection. Irrespective, these data suggest that LL-37
does not inhibit virus replication by inducing an enhanced
inflammatory response over the course of the infection.
It seems likely that the decreased BAL fluid IL-1b concentration
(and overall decrease in other inflammatory cytokines) observed in
LL-37-treated infected mice is a consequence of peptide enhanced
early clearance of the virus by day 3 as demonstrated in Figure 1C.
However, the extent to which LL-37 might also directly modulate
cytokines in response to infection remains to be determined.
Nevertheless, these data demonstrate that therapeutic use of LL-37
provides enhanced protection against influenza virus, in the
absence of prolonged upregulation of potentially harmful inflam-
matory cytokines in the lung [56,57].
To examine whether cathelicidin peptides have antiviral activity
against influenza virus in the absence of a cellular immune
response, we tested their ability to reduce viral infectivity in cell
culture. Exposure of two different influenza viruses (A/PR/8/34
H1N1 and A/Udorn/307/72 H3N2) to concentrations of LL-37
peptide naturally found in the inflamed human lung [58,59]
resulted in significant (p#0.05) decreases in the number of plaque
forming units in both viruses. As well as demonstrating that the
antiviral effects of LL-37 were not limited to the PR/8 virus, these
data demonstrate that LL-37 can have antiviral activity in vitro and
indicate that LL-37 may have a direct effect on virus viability, or
adversely influence viral adherence, internalization or replication,
as shown for various defensins [2,60]. The murine mCRAMP
peptide also demonstrated significant anti-influenza activity, while
the porcine cathelicidin Protegrin-1 and scrambled LL-37 peptide
had no antiviral effect in vitro, correlating with the lack of
protection observed in vivo. In contrast, both D-LL-37 and D-
mCRAMP retained their potent antiviral activity in vitro and in vivo,
although at the dosages used, there was no statistically significant
advantage gained by using the metabolically more stable D-
analogs. This further supports the suggestion that physical
properties of the cathelicidin peptides, rather than interactions
with receptors, are involved in the antiviral effects of these
peptides.
In summary, this study demonstrates that cathelicidins possess
potent antiviral activity against influenza virus. This antiviral
activity is at least partially mediated by a direct effect on the virion,
with an as yet undetermined contribution from cathelicidin-
mediated immunomodulation. These data suggest that approaches
aimed at increasing natural cathelicidin expression in the
influenza-infected lung, or therapeutic treatment of influenza-
Figure 4. Cathelicidins show antiviral activity against influenza virus in vitro. Influenza virus was pre-incubated with cathelicidin peptide or
control peptide scrambled LL-37 (sLL-37) (A) at a range of concentrations as indicated for 1 hour at room temperature and a plaque formation assay
was then performed to assess virus titer in MDCK-L cells in the presence of trypsin. Viruses used were A/PR/8/34 (H1N1) (A, B) or A/Udorn/307/72 (C).
The antiviral activity of the cathelicidins LL-37 (A, C), mCRAMP (B) and Protegrin-1 (B) was assessed. Figures are representative of at least three
independent experiments. Figures show mean values 6 SEM. Statistical analysis was performed using an unpaired t-test to compare virus only titer
with virus + peptide (*P#0.05, ** P#0.01).
doi:10.1371/journal.pone.0025333.g004
LL-37 and Influenza
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e25333
infected individuals may provide significant protection against
disease. Such approaches may include increasing vitamin-D levels
to boost endogenous cathelicidin production or the therapeutic
administration of naturally-occurring cathelicidins or synthetic
analogues such as D-form peptides (which show greater stability
against proteases) or peptides modified to maximize the key anti-
influenza functions.
Materials and Methods
Animals & Ethics Statement
6 to 8 week old female BALB/c mice were supplied by Jackson
Laboratories, USA and housed and handled per approved
protocols in compliance to the CDC Institutional Animal Care
and Use Committee guidelines (IACUC 2064DONMOU).
Viruses and Cells
A/Puerto Rico/8/1934 (H1N1) and A/Udorn/307/72 (H3N2)
viruses were propagated and titrated as described previously [61].
Madin Darby Canine Kidney (MDCK) cells were obtained from
the Amerian Type Culture Collection (Manassas, VA).
Infection and Nebulization
Mice were lightly anaesthetized with 1.5% isoflurane and
inoculated with 10 median lethal doses (MLD50) of A/Puerto
Rico/8/1934 (H1N1) (approximately 350 plaque forming units)
by intranasal instillation of 50 ml of virus suspension. For
nebulization, mice were briefly anaesthetized with 1.5% isoflurane
and placed into a cylindrical exposure chamber with their nose
protruding through a nasal cone at the top of the chamber. A
Figure 5. D-Isomer cathelicidins inhibit influenza virus. (A,B) Groups of 5 mice were infected with 10 MLD50 of A/PR/8/34 influenza virus via
intranasal administration on day 0. Mice were nebulized with 200 ml of saline (control), zanamivir (500 mg/ml), D-LL-37 peptide (500 mg/ml) or D-
mCRAMP peptide (500 mg/ml) once daily from day -1 to day 7. Mouse weight and survival was monitored daily up to 14 days post infection. Data
represent mean values6 SEM from n=1 experiment. Statistical analysis was performed using Kaplan Meier with a Mantel-Cox (log rank) test. Survival
curves obtained with Zanamivir, D-LL-37 and D-mCRAMP treatments were significantly different (P#0.001) compared to saline control treatment.
(C) Groups of 5 mice were infected with 10MLD50 of A/PR/8/34 virus via intranasal administration on day 0. Mice were nebulized with 200 ml of
saline (control), zanamivir (500 mg/ml), D-LL-37 peptide (500 mg/ml) or D-mCRAMP peptide (500 mg/ml) once daily from day -1 to day 2. Mice were
euthanized on day 3 and viral titer in the lungs was assessed by plaque assay. Figure is representative of n = 3 independent experiments. Figure
shows mean values 6 SEM. Statistical analysis was performed using an unpaired t-test to compare virus infected animals with virus/peptide and
virus/zanamivir treated animals (*P#0.05). (D) The antiviral activity of the cathelicidins D-LL-37 and D-mCRAMP was assessed. Figure is representative
of n= 3 independent experiments. Figure shows mean values 6 SEM. Statistical analysis was performed using an unpaired t-test to compare PR/8
only titer with PR/8 + Peptide (*P#0.05, ** P#0.01).
doi:10.1371/journal.pone.0025333.g005
LL-37 and Influenza
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nebulizer unit (Kent Scientific, CN, USA) was connected to the
top of the exposure chamber and mice were exposed to either
CHDP suspended in endotoxin-free water as indicated, or water-
only control for 30 seconds. Mice were then removed from
exposure chamber and allowed to recover. Mice were monitored
daily until 14 d.p.i for mortality and weight loss. Mice that lost
.25% of their initial body weight were euthanized in accordance
with our approved animal study protocol.
Viral Titer Assessment
Mouse lung viral titers were measured 3 days post infection.
Briefly, mice were euthanized 3 days post infection and tissues
were extracted and stored at 280uC. Lung tissue was homoge-
nized in 1 ml ice cold PBS using a MagNA Lyser tissue
homogenizer (Roche, IN, USA). Homogenates were clarified by
centrifugation at 10,000 x g for 5 minutes and the viral titer of the
supernatant was assessed by plaque formation assay in MDCK-L
cells in the presence of trypsin [61].
Cytokine Analysis
Measurement of cytokine concentration in the bronchoalveolar
lavage fluid was performed via Bioplex analysis. Briefly, mice were
euthanized 3 days post infection and bronchoalveolar lavage was
performed in situ using 1 ml sterile ice cold PBS. Samples were
aliquoted and frozen at 280uC until use. Cytokine analysis was
then performed using a BioPlex Mouse Cytokine Assay Kit (Bio-
Rad, CA, USA) according to manufacturer’s instructions.
Peptide Synthesis and Purification
The peptides were assembled using the Fmoc/tBu solid-phase
peptide synthesis approach [62] using either model 433A (Applied
Biosystems, CA, USA) or model Liberty (CEM Corporation, NC,
USA) automated peptide synthesizers followed by cleavage in the
trifluoroacetic acid (TFA) / phenol / thioanisole / ethanedithiol/
water (10:0.75:0.5:0.25:0.5, w/w) mixture at 25uC for 90 min
followed by precipitation with cold diethyl ether. The crude
peptides were purified by preparative reversed-phase high-
pressure liquid chromatography (RP-HPLC). The peptide purity
(.98%) was confirmed by analytical RP-HPLC, and the masses
were confirmed by mass spectrometry. Following lyophilization,
the purified peptides were obtained in the form of their TFA salts;
namely: LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN-
LVPRTES), LL-37 analog having ‘‘scrambled’’ sequence (RSLE-
GTDRFPFVRLKNSRKLEFKDIKGIKREQFVKIL), termed
sLL-37 (control peptide), mouse cathelicidin mCRAMP (GLLR-
KGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ), and their all-
D-amino acid residues containing analogs, D-LL-37 and D-
mCRAMP. Since porcine Protegrin-1 (PG-1;
RGGRLCYCRRRFCVCVGR –amide) was obtained in its
reduced form, its two disulfide bridges, connecting Cys-6 and
Cys-15, and Cys-8 and Cys-13, were formed by air oxidation of
the HPLC purified, all-reduced peptide. The antimicrobial
activity of the preparations of LL-37, mCRAMP, and Prote-
grin-1 peptides was confirmed in the antibacterial assays against
Neisseria gonorrhoeae (FA19), Acinetobacter baumannii, and Staphylococcus
aureus (COL) (data not shown).
In Vitro Antiviral Activity of Cathelicidins
To assess in vitro effects of peptides on influenza virus, A/Puerto
Rico/8/1934 (H1N1) virus and A/Udorn/307/72 (H3N2) were
exposed to peptides for 1 hour at room temperature in DMEM.
Ten-fold serial dilutions in DMEM were then performed to assess
the resulting viral titer by plaque formation assay in MDCK-L
cells in the presence of trypsin in the agarose overlay.
Statistical Analysis
Statistical analysis of the data was performed using GraphPad
Prism software. Survival curves were analysed using Kaplan Meier
with a Mantel-Cox (log rank) test. Weight loss between treatment
groups was assessed at day 7 by an unpaired t-test comparing virus
infected animals with virus/peptide and virus/zanamivir treated
animals. Statistical analysis of the alterations in lung virus titer as a
result of peptide treatment was performed using an unpaired t-test
to compare virus infected animals with virus/peptide and virus/
zanamivir treated animals.
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